BioSpace News Archive

BIOREM Inc. (TSX-V: BRM) (“BIOREM” or “the Company”) announces that due to circumstances created by the Covid-19 pandemic, it will be postponing its reporting of the Company’s audited financial statements, accompanying management’s discussion and analysis, and related CEO and CFO certifications for the year ended December 31, 2019

US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC (USPI) announced today that the Jerome Canady Research Institute for Advanced Biological & Technological Sciences (JCRI-ABTS), a research partner for USPI/USMI, is seeking approval from the Food and Drug Administration (FDA) under its Emergency Use Authorization (EUA) for using the Canady HeliosTM Cold Plasma HERO

Prothena Corporation plc, a clinical-stage neuroscience company with expertise in protein misfolding, announced that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after the close of the U.S. financial markets..

North American Dental Group, a leading U.S. Dental Service Organization, announced that it plans to convert hundreds of currently closed affiliated dental offices to much-needed COVID-19 testing sites to relieve the pressure on overstressed hospital ER rooms and increase availability of the tests to the public.

ELT Sight, Inc. today announced that the American Medical Association (AMA) approved two new Category III Current Procedural Terminology (CPT®) codes to report ELT Sight’s ExTra Excimer Laser Trabeculostomy (ELT) procedure.

Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company’s financial results at 8:00 a.m.

TraceLink Inc., the leading digital platform company for the life science supply chain, today announced continued customer adoption, with over 160 companies using its saleable returns verification solution

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2 PR001 PROVIDE and PR006 PROCLAIM Clinical Trials NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced

Vaccine will be delivered via a dermal patch applied to skin Verndari’s VaxiPatch™ microneedle patch technology enables mass production of vaccination kits

I-Mab today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2019 with the U.S. Securities and Exchange Commission